{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T12:57:58Z","timestamp":1790859478332,"version":"4.1.0"},"reference-count":91,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,13]],"date-time":"2025-01-13T00:00:00Z","timestamp":1736726400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,1,13]],"date-time":"2025-01-13T00:00:00Z","timestamp":1736726400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Cardiol Rep"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s11886-024-02181-9","type":"journal-article","created":{"date-parts":[[2025,1,13]],"date-time":"2025-01-13T07:40:00Z","timestamp":1736754000000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Metabolic Dysfunction Associated-Steatotic Liver Disease (MASLD) and Cardiovascular Risk: Embrace All Facets of the Disease"],"prefix":"10.1007","volume":"27","author":[{"given":"Niki","family":"Katsiki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Genovefa","family":"Kolovou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michal","family":"Vrablik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,13]]},"reference":[{"issue":"1","key":"2181_CR1","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.jhep.2020.03.039","volume":"73","author":"M Eslam","year":"2020","unstructured":"Eslam M, Newsome PN, Sarin SK, Anstee QM, Targher G, Romero-Gomez M, Zelber-Sagi S, Wai-Sun Wong V, Dufour JF, Schattenberg JM, Kawaguchi T, Arrese M, Valenti L, Shiha G, Tiribelli C, Yki-J\u00e4rvinen H, Fan JG, Gr\u00f8nb\u00e6k H, Yilmaz Y, Cortez-Pinto H, Oliveira CP, Bedossa P, Adams LA, Zheng MH, Fouad Y, Chan WK, Mendez-Sanchez N, Ahn SH, Castera L, Bugianesi E, Ratziu V, George J. A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement. J Hepatol. 2020;73(1):202\u20139.","journal-title":"J Hepatol"},{"issue":"7","key":"2181_CR2","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1016\/j.eprac.2022.03.016","volume":"28","author":"J Quek","year":"2022","unstructured":"Quek J, Ng CH, Tang ASP, Chew N, Chan M, Khoo CM, Wei CP, Chin YH, Tay P, Lim G, Tan DJH, Lim WH, Chan KE, Teng M, Tan E, Tamaki N, Huang DQ, Siddiqui MS, Young DY, Noureddin M, Muthiah MD. Metabolic associated fatty liver disease increases the risk of systemic complications and mortality. A meta-analysis and systematic review of 12 620 736 individuals. Endocr Pract. 2022;28(7):667\u201372.","journal-title":"Endocr Pract."},{"issue":"8","key":"2181_CR3","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1177\/0003319713481101","volume":"64","author":"VG Athyros","year":"2013","unstructured":"Athyros VG, Katsiki N, Karagiannis A. Nonalcoholic fatty liver disease and severity of cardiovascular disease manifestations. Angiology. 2013;64(8):572\u20135.","journal-title":"Angiology"},{"key":"2181_CR4","doi-asserted-by":"crossref","unstructured":"European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines for the Management of Non-Alcoholic Fatty Liver Disease. Obes Facts. 2016;9(2):65\u201390.","DOI":"10.1159\/000443344"},{"issue":"2","key":"2181_CR5","doi-asserted-by":"publisher","first-page":"299","DOI":"10.21037\/hbsn-21-548","volume":"11","author":"E Kaya","year":"2022","unstructured":"Kaya E, Zedginidze A, Bechmann L, Canbay A. Metabolic dysfunction-associated fatty liver disease (MAFLD) and non-alcoholic fatty liver disease (NAFLD): distinct fatty liver entities with different clinical outcomes? Hepatobiliary Surg Nutr. 2022;11(2):299\u2013301.","journal-title":"Hepatobiliary Surg Nutr"},{"key":"2181_CR6","doi-asserted-by":"publisher","first-page":"154010","DOI":"10.1016\/j.metabol.2019.154010","volume":"101","author":"N Katsiki","year":"2019","unstructured":"Katsiki N, Gastaldelli A, Mikhailidis DP. Predictive models with the use of omics and supervised machine learning to diagnose non-alcoholic fatty liver disease: A \u201cnon-invasive alternative\u201d to liver biopsy? Metabolism. 2019;101:154010.","journal-title":"Metabolism"},{"issue":"6","key":"2181_CR7","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.1097\/HEP.0000000000000520","volume":"78","author":"ME Rinella","year":"2023","unstructured":"Rinella ME, Lazarus JV, Ratziu V, Francque SM, Sanyal AJ, Kanwal F, Romero D, Abdelmalek MF, Anstee QM, Arab JP, Arrese M, Bataller R, Beuers U, Boursier J, Bugianesi E, Byrne CD, Castro Narro GE, Chowdhury A, Cortez-Pinto H, Cryer DR, Cusi K, El-Kassas M, Klein S, Eskridge W, Fan J, Gawrieh S, Guy CD, Harrison SA, Kim SU, Koot BG, Korenjak M, Kowdley KV, Lacaille F, Loomba R, Mitchell-Thain R, Morgan TR, Powell EE, Roden M, Romero-G\u00f3mez M, Silva M, Singh SP, Sookoian SC, Spearman CW, Tiniakos D, Valenti L, Vos MB, Wong VW, Xanthakos S, Yilmaz Y, Younossi Z, Hobbs A, Villota-Rivas M, Newsome PN. NAFLD Nomenclature consensus group. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Hepatology. 2023;78(6):1966\u201386.","journal-title":"Hepatology"},{"key":"2181_CR8","doi-asserted-by":"publisher","first-page":"155664","DOI":"10.1016\/j.metabol.2023.155664","volume":"147","author":"M Kokkorakis","year":"2023","unstructured":"Kokkorakis M, Boutari C, Katsiki N, Mantzoros CS. From non-alcoholic fatty liver disease (NAFLD) to steatotic liver disease (SLD): an ongoing journey towards refining the terminology for this prevalent metabolic condition and unmet clinical need. Metabolism. 2023;147:155664.","journal-title":"Metabolism"},{"key":"2181_CR9","unstructured":"European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). J Hepatol. 2024;S0168\u20138278(24):00329\u20135."},{"issue":"22","key":"2181_CR10","doi-asserted-by":"publisher","first-page":"6820","DOI":"10.3748\/wjg.v21.i22.6820","volume":"21","author":"VG Athyros","year":"2015","unstructured":"Athyros VG, Tziomalos K, Katsiki N, Doumas M, Karagiannis A, Mikhailidis DP. Cardiovascular risk across the histological spectrum and the clinical manifestations of non-alcoholic fatty liver disease: An update. World J Gastroenterol. 2015;21(22):6820\u201334.","journal-title":"World J Gastroenterol"},{"issue":"4","key":"2181_CR11","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1097\/HCO.0000000000000068","volume":"29","author":"N Katsiki","year":"2014","unstructured":"Katsiki N, Athyros VG, Karagiannis A, Wierzbicki AS, Mikhailidis DP. Should we expand the concept of coronary heart disease equivalents? Curr Opin Cardiol. 2014;29(4):389\u201395.","journal-title":"Curr Opin Cardiol"},{"issue":"8","key":"2181_CR12","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1016\/j.metabol.2016.05.003","volume":"65","author":"N Katsiki","year":"2016","unstructured":"Katsiki N, Mikhailidis DP, Mantzoros CS. Non-alcoholic fatty liver disease and dyslipidemia: An update. Metabolism. 2016;65(8):1109\u201323.","journal-title":"Metabolism"},{"issue":"3","key":"2181_CR13","doi-asserted-by":"publisher","first-page":"219","DOI":"10.2174\/1570161115666170621075619","volume":"16","author":"N Katsiki","year":"2018","unstructured":"Katsiki N, Perez-Martinez P, Anagnostis P, Mikhailidis DP, Karagiannis A. Is Nonalcoholic Fatty Liver Disease Indeed the Hepatic Manifestation of Metabolic Syndrome? Curr Vasc Pharmacol. 2018;16(3):219\u201327.","journal-title":"Curr Vasc Pharmacol"},{"key":"2181_CR14","first-page":"17","volume":"71","author":"VG Athyros","year":"2017","unstructured":"Athyros VG, Alexandrides TK, Bilianou H, Cholongitas E, Doumas M, Ganotakis ES, Goudevenos J, Elisaf MS, Germanidis G, Giouleme O, Karagiannis A, Karvounis C, Katsiki N, Kotsis V, Kountouras J, Liberopoulos E, Pitsavos C, Polyzos S, Rallidis LS, Richter D, Tsapas AG, Tselepis AD, Tsioufis K, Tziomalos K, Tzotzas T, Vasiliadis TG, Vlachopoulos C, Mikhailidis DP, Mantzoros C. The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease\/non-alcoholic steatohepatitis and related cardiovascular risk. An Expert Panel Statement Metabolism. 2017;71:17\u201332.","journal-title":"An Expert Panel Statement Metabolism"},{"issue":"Suppl 2","key":"2181_CR15","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1111\/dom.14484","volume":"24","author":"CD Byrne","year":"2022","unstructured":"Byrne CD, Targher G. Non-alcoholic fatty liver disease-related risk of cardiovascular disease and other cardiac complications. Diabetes Obes Metab. 2022;24(Suppl 2):28\u201343.","journal-title":"Diabetes Obes Metab"},{"issue":"8","key":"2181_CR16","first-page":"1189","volume":"12","author":"GD Cazac","year":"2022","unstructured":"Cazac GD, L\u0103c\u0103tu\u0219u CM, Mihai C, Grigorescu ED, Onofriescu A, Mihai BM. New Insights into Non-Alcoholic Fatty Liver Disease and Coronary Artery Disease: The Liver-Heart Axis. Life (Basel). 2022;12(8):1189.","journal-title":"Life (Basel)"},{"issue":"1","key":"2181_CR17","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1002\/hep.32534","volume":"77","author":"Z Ren","year":"2023","unstructured":"Ren Z, Simons PIHG, Wesselius A, Stehouwer CDA, Brouwers MCGJ. Relationship between NAFLD and coronary artery disease: A Mendelian randomization study. Hepatology. 2023;77(1):230\u20138.","journal-title":"Hepatology"},{"issue":"7","key":"2181_CR18","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1007\/s00392-020-01709-7","volume":"110","author":"P Kasper","year":"2021","unstructured":"Kasper P, Martin A, Lang S, K\u00fctting F, Goeser T, Demir M, Steffen HM. NAFLD and cardiovascular diseases: a clinical review. Clin Res Cardiol. 2021;110(7):921\u201337.","journal-title":"Clin Res Cardiol"},{"issue":"1","key":"2181_CR19","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1186\/s12933-022-01518-4","volume":"21","author":"Y Matsubayashi","year":"2022","unstructured":"Matsubayashi Y, Fujihara K, Yamada-Harada M, Mitsuma Y, Sato T, Yaguchi Y, Osawa T, Yamamoto M, Kitazawa M, Yamada T, Kodama S, Sone H. Impact of metabolic syndrome and metabolic dysfunction-associated fatty liver disease on cardiovascular risk by the presence or absence of type 2 diabetes and according to sex. Cardiovasc Diabetol. 2022;21(1):90.","journal-title":"Cardiovasc Diabetol"},{"issue":"5","key":"2181_CR20","doi-asserted-by":"publisher","first-page":"101468","DOI":"10.1016\/j.diabet.2023.101468","volume":"49","author":"S Chen","year":"2023","unstructured":"Chen S, Xue H, Huang R, Chen K, Zhang H, Chen X. Associations of MAFLD and MAFLD subtypes with the risk of the incident myocardial infarction and stroke. Diabetes Metab. 2023;49(5):101468.","journal-title":"Diabetes Metab"},{"issue":"4","key":"2181_CR21","doi-asserted-by":"publisher","first-page":"101511","DOI":"10.1016\/j.aohep.2024.101511","volume":"29","author":"L Vega","year":"2024","unstructured":"Vega L, Simian D, Gajardo AI, Salinas M, Urra A, Cattaneo M, Pino R, Roblero JP, Urz\u00faa \u00c1, Rojas K, Poniachik J. Coronary artery disease as a risk factor for metabolic dysfunction-associated steatotic liver disease and liver fibrosis. Ann Hepatol. 2024;29(4):101511.","journal-title":"Ann Hepatol"},{"issue":"3","key":"2181_CR22","first-page":"77","volume":"11","author":"RI Orzan","year":"2024","unstructured":"Orzan RI, Gligor RI, Agoston R, Cionca C, Zlibut A, Pais R, Seicean A, Agoston-Coldea L. Metabolic Dysfunction Associated Liver Disease in Patients Undergoing Coronary Computed Tomography Angiography. J Cardiovasc Dev Dis. 2024;11(3):77.","journal-title":"J Cardiovasc Dev Dis"},{"issue":"4","key":"2181_CR23","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1097\/HCO.0b013e3283605fba","volume":"28","author":"N Katsiki","year":"2013","unstructured":"Katsiki N, Mikhailidis DP, Wierzbicki AS. Epicardial fat and vascular risk: a narrative review. Curr Opin Cardiol. 2013;28(4):458\u201363.","journal-title":"Curr Opin Cardiol"},{"issue":"5","key":"2181_CR24","doi-asserted-by":"publisher","first-page":"432","DOI":"10.2174\/1570161114666160722112738","volume":"14","author":"N Katsiki","year":"2016","unstructured":"Katsiki N, Athyros VG, Mikhailidis DP. Abnormal Peri-Organ or Intra-organ Fat (APIFat) Deposition: An Underestimated Predictor of Vascular Risk? Curr Vasc Pharmacol. 2016;14(5):432\u201341.","journal-title":"Curr Vasc Pharmacol"},{"issue":"4","key":"2181_CR25","doi-asserted-by":"publisher","first-page":"108419","DOI":"10.1016\/j.jdiacomp.2023.108419","volume":"37","author":"N Katsiki","year":"2023","unstructured":"Katsiki N, Rizzo M, Mikhailidis DP. Epicardial, peripancreatic and other \u201corthotopic\u201d excessive fat deposition in south Asians and Europeans: Are differences clinically relevant? J Diabetes Complications. 2023;37(4):108419.","journal-title":"J Diabetes Complications"},{"issue":"3","key":"2181_CR26","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1177\/00033197211014676","volume":"73","author":"N Katsiki","year":"2022","unstructured":"Katsiki N, Mikhailidis DP. Perivascular Adipose Tissue: Pathophysiological Links With Inflammation, Atherosclerosis, and Thrombosis. Angiology. 2022;73(3):195\u20136.","journal-title":"Angiology"},{"issue":"7","key":"2181_CR27","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1177\/0003319719848204","volume":"70","author":"N Katsiki","year":"2019","unstructured":"Katsiki N, Dimitriadis G, Mikhailidis DP. Perirenal Adiposity and Other Excessive Intra- and Peri-Organ Fat Depots: What Is the Connection? Angiology. 2019;70(7):581\u20133.","journal-title":"Angiology"},{"issue":"1","key":"2181_CR28","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1007\/s10620-021-06824-7","volume":"67","author":"TD Filippatos","year":"2022","unstructured":"Filippatos TD, Alexakis K, Mavrikaki V, Mikhailidis DP. Nonalcoholic fatty pancreas disease: Role in metabolic syndrome, \u201cPrediabetes,.\u201d Diabetes Atherosclerosis Dig Dis Sci. 2022;67(1):26\u201341.","journal-title":"Diabetes Atherosclerosis Dig Dis Sci"},{"key":"2181_CR29","first-page":"100386","volume":"41","author":"AJ Sanyal","year":"2024","unstructured":"Sanyal AJ, Husain M, Diab C, Mangla KK, Shoeb A, Lingvay I, Tapper EB. Cardiovascular disease in patients with metabolic dysfunction-associated steatohepatitis compared with metabolic dysfunction-associated steatotic liver disease and other liver diseases: A systematic review. Am Heart J Plus. 2024;41:100386.","journal-title":"Am Heart J Plus"},{"issue":"1","key":"2181_CR30","doi-asserted-by":"publisher","first-page":"7224","DOI":"10.1038\/s41598-023-34462-8","volume":"13","author":"Z Zhang","year":"2023","unstructured":"Zhang Z, Zheng M, Lei H, Jiang Z, Chen Y, He H, Zhao G, Huang H. A clinical study of the correlation between metabolic-associated fatty liver disease and coronary plaque pattern. Sci Rep. 2023;13(1):7224.","journal-title":"Sci Rep"},{"key":"2181_CR31","doi-asserted-by":"publisher","unstructured":"De Filippo O, Di Pietro G, Nebiolo M, Ribaldone DG, Gatti M, Bruno F, Gallone G, Armandi A, Birtolo LI, Zullino V, Mennini G, Corradini SG, Mancone M, Bugianesi E, Iannaccone M, De Ferrari GM, D'Ascenzo F. Increased prevalence of high-risk coronary plaques in metabolic dysfunction associated stetatotic liver disease patients: A meta-analysis. Eur J Clin Invest. 2024;e14188. https:\/\/doi.org\/10.1111\/eci.14188","DOI":"10.1111\/eci.14188"},{"key":"2181_CR32","doi-asserted-by":"publisher","first-page":"2627","DOI":"10.2147\/DMSO.S426102","volume":"16","author":"C Lu","year":"2023","unstructured":"Lu C, Chen Y, Zhang Y, Zhao X. Liver Fibrosis Scores and Coronary Artery Disease: Novel Findings in Patients with Metabolic Dysfunction-Associated Fatty Liver Disease. Diabetes Metab Syndr Obes. 2023;16:2627\u201337.","journal-title":"Diabetes Metab Syndr Obes"},{"issue":"1","key":"2181_CR33","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/s13098-023-01031-y","volume":"15","author":"M Namakchian","year":"2023","unstructured":"Namakchian M, Rabizadeh S, Seifouri S, Asadigandomani H, Bafrani MA, Seifouri K, Avanaki FA, Rajab A, Nakhjavani M, Esteghamati A. Fibrosis score 4 index has an independent relationship with coronary artery diseases in patients with metabolic-associated fatty liver disease. Diabetol Metab Syndr. 2023;15(1):57.","journal-title":"Diabetol Metab Syndr"},{"issue":"1","key":"2181_CR34","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1186\/s13098-023-01102-0","volume":"15","author":"Z Wei","year":"2023","unstructured":"Wei Z, Huang Z, Song Z, Zhao W, Zhao D, Tan Y, Chen S, Yang P, Li Y, Wu S. Metabolic Dysfunction-associated fatty liver disease and incident heart failure risk: the Kailuan cohort study. Diabetol Metab Syndr. 2023;15(1):137.","journal-title":"Diabetol Metab Syndr"},{"issue":"1","key":"2181_CR35","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s13098-023-01006-z","volume":"15","author":"SE Lee","year":"2023","unstructured":"Lee SE, Yoo J, Kim BS, Choi HS, Han K, Kim KA. The effect of metabolic dysfunction-associated fatty liver disease and diabetic kidney disease on the risk of hospitalization of heart failure in type 2 diabetes: a retrospective cohort study. Diabetol Metab Syndr. 2023;15(1):32.","journal-title":"Diabetol Metab Syndr"},{"issue":"2","key":"2181_CR36","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/j.jacc.2021.11.007","volume":"79","author":"A Mantovani","year":"2022","unstructured":"Mantovani A, Byrne CD, Benfari G, Bonapace S, Simon TG, Targher G. Risk of Heart Failure in Patients With Nonalcoholic Fatty Liver Disease: JACC Review Topic of the Week. J Am Coll Cardiol. 2022;79(2):180\u201391.","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"2181_CR37","doi-asserted-by":"publisher","first-page":"12440","DOI":"10.1038\/s41598-020-69013-y","volume":"10","author":"A Miller","year":"2020","unstructured":"Miller A, McNamara J, Hummel SL, Konerman MC, Tincopa MA. Prevalence and staging of non-alcoholic fatty liver disease among patients with heart failure with preserved ejection fraction. Sci Rep. 2020;10(1):12440.","journal-title":"Sci Rep"},{"issue":"2","key":"2181_CR38","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1002\/ehf2.13222","volume":"8","author":"R Itier","year":"2021","unstructured":"Itier R, Guillaume M, Ricci JE, Roubille F, Delarche N, Picard F, Galinier M, Roncalli J. Non-alcoholic fatty liver disease and heart failure with preserved ejection fraction: from pathophysiology to practical issues. ESC Heart Fail. 2021;8(2):789\u201398.","journal-title":"ESC Heart Fail"},{"issue":"11","key":"2181_CR39","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1016\/j.jacbts.2021.07.010","volume":"6","author":"HM Salah","year":"2021","unstructured":"Salah HM, Pandey A, Soloveva A, Abdelmalek MF, Diehl AM, Moylan CA, Wegermann K, Rao VN, Hernandez AF, Tedford RJ, Parikh KS, Mentz RJ, McGarrah RW, Fudim M. Relationship of Nonalcoholic Fatty Liver Disease and Heart Failure With Preserved Ejection Fraction. JACC Basic Transl Sci. 2021;6(11):918\u201332.","journal-title":"JACC Basic Transl Sci"},{"issue":"6","key":"2181_CR40","first-page":"e62441","volume":"16","author":"D Ugwendum","year":"2024","unstructured":"Ugwendum D, Mohamed M, Al-Ajlouni YA, Nso N, Njei B. Association of metabolic dysfunction-associated steatotic liver disease (masld) with an increased risk of congestive heart failure in hospitalized patients with cirrhosis: A propensity score-matched analysis. Cureus. 2024;16(6):e62441.","journal-title":"Cureus"},{"issue":"8","key":"2181_CR41","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1016\/j.cgh.2024.03.045","volume":"22","author":"TJ Hydes","year":"2024","unstructured":"Hydes TJ, Kennedy OJ, Glyn-Owen K, Buchanan R, Parkes J, Cuthbertson DJ, Roderick P, Byrne CD. Liver Fibrosis Assessed Via Noninvasive Tests Is Associated With Incident Heart Failure in a General Population Cohort. Clin Gastroenterol Hepatol. 2024;22(8):1657\u201367.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2181_CR42","doi-asserted-by":"publisher","first-page":"1160532","DOI":"10.3389\/fendo.2023.1160532","volume":"14","author":"BG Zhou","year":"2023","unstructured":"Zhou BG, Ju SY, Mei YZ, Jiang X, Wang M, Zheng AJ, Ding YB. A systematic review and meta-analysis of cohort studies on the potential association between NAFLD\/MAFLD and risk of incident atrial fibrillation. Front Endocrinol (Lausanne). 2023;14:1160532.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"6","key":"2181_CR43","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1177\/10815589231164777","volume":"71","author":"V Jaiswal","year":"2023","unstructured":"Jaiswal V, Ang SP, Huang H, Momi NK, Hameed M, Naz S, Batra N, Ishak A, Doshi N, Gera A, Sharath M, Waleed MS, Raj N, Aguilera Alvarez VH. Association between nonalcoholic fatty liver disease and atrial fibrillation and other clinical outcomes: a meta-analysis. J Investig Med. 2023;71(6):591\u2013602.","journal-title":"J Investig Med"},{"issue":"10","key":"2181_CR44","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1016\/j.jacep.2020.05.023","volume":"6","author":"E Donnellan","year":"2020","unstructured":"Donnellan E, Cotter TG, Wazni OM, Elshazly MB, Kochar A, Wilner B, Patel D, Kanj M, Hussein A, Baranowski B, Cantillon D, Griffin B, Jaber W, Saliba WI. Impact of Nonalcoholic Fatty Liver Disease on Arrhythmia Recurrence Following Atrial Fibrillation Ablation. JACC Clin Electrophysiol. 2020;6(10):1278\u201387.","journal-title":"JACC Clin Electrophysiol"},{"key":"2181_CR45","doi-asserted-by":"publisher","first-page":"957245","DOI":"10.3389\/fendo.2022.957245","volume":"13","author":"R Decoin","year":"2022","unstructured":"Decoin R, Butruille L, Defrancq T, Robert J, Destrait N, Coisne A, Aghezzaf S, Woitrain E, Gouda Z, Schino S, Klein C, Maboudou P, Brigadeau F, Klug D, Vincentelli A, Dombrowicz D, Staels B, Montaigne D, Ninni S. High liver fibrosis scores in metabolic dysfunction-associated fatty liver disease patients are associated with adverse atrial remodeling and atrial fibrillation recurrence following catheter ablation. Front Endocrinol (Lausanne). 2022;13:957245.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"1","key":"2181_CR46","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1186\/s12933-023-02070-5","volume":"22","author":"TG Simon","year":"2023","unstructured":"Simon TG, Ebrahimi F, Roelstraete B, Hagstr\u00f6m H, Sundstr\u00f6m J, Ludvigsson JF. Incident cardiac arrhythmias associated with metabolic dysfunction-associated steatotic liver disease: a nationwide histology cohort study. Cardiovasc Diabetol. 2023;22(1):343.","journal-title":"Cardiovasc Diabetol"},{"key":"2181_CR47","doi-asserted-by":"publisher","first-page":"155294","DOI":"10.1016\/j.metabol.2022.155294","volume":"136","author":"J Ye","year":"2022","unstructured":"Ye J, Zhuang X, Li X, Gong X, Sun Y, Wang W, Feng S, Wu T, Zhong B. Novel metabolic classification for extrahepatic complication of metabolic associated fatty liver disease: A data-driven cluster analysis with international validation. Metabolism. 2022;136:155294.","journal-title":"Metabolism"},{"issue":"3","key":"2181_CR48","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1136\/gutjnl-2023-331003","volume":"73","author":"HH Lee","year":"2024","unstructured":"Lee HH, Lee HA, Kim EJ, Kim HY, Kim HC, Ahn SH, Lee H, Kim SU. Metabolic dysfunction-associated steatotic liver disease and risk of cardiovascular disease. Gut. 2024;73(3):533\u201340.","journal-title":"Gut"},{"issue":"10","key":"2181_CR49","doi-asserted-by":"publisher","first-page":"2138","DOI":"10.1016\/j.cgh.2020.12.022","volume":"19","author":"H Lee","year":"2021","unstructured":"Lee H, Lee YH, Kim SU, Kim HC. Metabolic Dysfunction-Associated Fatty Liver Disease and Incident Cardiovascular Disease Risk: A Nationwide Cohort Study. Clin Gastroenterol Hepatol. 2021;19(10):2138\u201347.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"3","key":"2181_CR50","doi-asserted-by":"publisher","first-page":"483","DOI":"10.3350\/cmh.2021.0406","volume":"28","author":"ASP Tang","year":"2022","unstructured":"Tang ASP, Chan KE, Quek J, Xiao J, Tay P, Teng M, Lee KS, Lin SY, Myint MZ, Tan B, Sharma VK, Tan DJH, Lim WH, Kaewdech A, Huang D, Chew NW, Siddiqui MS, Sanyal AJ, Muthiah M, Ng CH. Non-alcoholic fatty liver disease increases risk of carotid atherosclerosis and ischemic stroke: An updated meta-analysis with 135,602 individuals. Clin Mol Hepatol. 2022;28(3):483\u201396.","journal-title":"Clin Mol Hepatol"},{"issue":"9","key":"2181_CR51","doi-asserted-by":"publisher","first-page":"1867","DOI":"10.1136\/gutjnl-2021-325724","volume":"71","author":"TG Simon","year":"2022","unstructured":"Simon TG, Roelstraete B, Hagstr\u00f6m H, Sundstr\u00f6m J, Ludvigsson JF. Non-alcoholic fatty liver disease and incident major adverse cardiovascular events: results from a nationwide histology cohort. Gut. 2022;71(9):1867\u201375.","journal-title":"Gut"},{"issue":"1","key":"2181_CR52","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1161\/STROKEAHA.120.030433","volume":"52","author":"J Xu","year":"2021","unstructured":"Xu J, Dai L, Zhang Y, Wang A, Li H, Wang Y, Meng X, Wu S, Wang Y. Severity of Nonalcoholic Fatty Liver Disease and Risk of Future Ischemic Stroke Events. Stroke. 2021;52(1):103\u201310.","journal-title":"Stroke"},{"issue":"6","key":"2181_CR53","doi-asserted-by":"publisher","first-page":"101643","DOI":"10.1016\/j.cpcardiol.2023.101643","volume":"48","author":"G Bisaccia","year":"2023","unstructured":"Bisaccia G, Ricci F, Khanji MY, Sorella A, Melchiorre E, Iannetti G, Galanti K, Mantini C, Pizzi AD, Tana C, Renda G, Fedorowski A, De Caterina R, Gallina S. Cardiovascular Morbidity and Mortality Related to Non-alcoholic Fatty Liver Disease: A Systematic Review and Meta-analysis. Curr Probl Cardiol. 2023;48(6):101643.","journal-title":"Curr Probl Cardiol"},{"issue":"5","key":"2181_CR54","doi-asserted-by":"publisher","first-page":"1534","DOI":"10.1111\/ene.15277","volume":"29","author":"M Wu","year":"2022","unstructured":"Wu M, Zha M, Lv Q, Xie Y, Yuan K, Zhang X, Liu X. Non-alcoholic fatty liver disease and stroke: A Mendelian randomization study. Eur J Neurol. 2022;29(5):1534\u20137.","journal-title":"Eur J Neurol"},{"key":"2181_CR55","doi-asserted-by":"publisher","first-page":"155220","DOI":"10.1016\/j.metabol.2022.155220","volume":"133","author":"H Peng","year":"2022","unstructured":"Peng H, Wang S, Wang M, Ye Y, Xue E, Chen X, Wang X, Fan M, Gao W, Qin X, Wu Y, Chen D, Li J, Hu Y, Wang L, Wu T. Nonalcoholic fatty liver disease and cardiovascular diseases: A Mendelian randomization study. Metabolism. 2022;133:155220.","journal-title":"Metabolism"},{"key":"2181_CR56","doi-asserted-by":"publisher","first-page":"373","DOI":"10.2147\/DMSO.S394414","volume":"16","author":"XH Song","year":"2023","unstructured":"Song XH, Liu B, Lei F, Liu YM, Zhang X, Chen Z, Zhang P, Zhang XJ, She ZG, Cai J, Wang JH, Li H. The Association Between Metabolic Dysfunction-Associated Fatty Liver Disease and Peripheral Arterial Disease in the Chinese Population. Diabetes Metab Syndr Obes. 2023;16:373\u201384.","journal-title":"Diabetes Metab Syndr Obes"},{"issue":"10","key":"2181_CR57","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1111\/imj.13549","volume":"47","author":"Y Zou","year":"2017","unstructured":"Zou Y, Li X, Wang C, Wang J, Wang F, Ma L, You W, Li C. Association between non-alcoholic fatty liver disease and peripheral artery disease in patients with type 2 diabetes. Intern Med J. 2017;47(10):1147\u201353.","journal-title":"Intern Med J"},{"issue":"4","key":"2181_CR58","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1111\/dom.14616","volume":"24","author":"S Meyh\u00f6fer","year":"2022","unstructured":"Meyh\u00f6fer S, Eckert AJ, Hummel M, Laimer M, Roden M, Kress S, Seufert J, Meyh\u00f6fer SM, Holl RW. Elevated liver enzymes and comorbidities in type 2 diabetes: A multicentre analysis of 51 645 patients from the Diabetes Prospective Follow-up (DPV) database. Diabetes Obes Metab. 2022;24(4):727\u201332.","journal-title":"Diabetes Obes Metab"},{"issue":"8","key":"2181_CR59","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1007\/s40618-022-01792-9","volume":"45","author":"S Ciardullo","year":"2022","unstructured":"Ciardullo S, Bianconi E, Cannistraci R, Parmeggiani P, Marone EM, Perseghin G. Peripheral artery disease and all-cause and cardiovascular mortality in patients with NAFLD. J Endocrinol Invest. 2022;45(8):1547\u201353.","journal-title":"J Endocrinol Invest"},{"key":"2181_CR60","doi-asserted-by":"publisher","first-page":"e45050","DOI":"10.2196\/45050","volume":"9","author":"S Wei","year":"2023","unstructured":"Wei S, Song J, Xie Y, Huang J, Yang J. The Role of Metabolic Dysfunction-Associated Fatty Liver Disease in Developing Chronic Kidney Disease: Longitudinal Cohort Study. JMIR Public Health Surveill. 2023;9:e45050.","journal-title":"JMIR Public Health Surveill"},{"key":"2181_CR61","doi-asserted-by":"publisher","first-page":"110563","DOI":"10.1016\/j.diabres.2023.110563","volume":"197","author":"S Wei","year":"2023","unstructured":"Wei S, Song J, Xie Y, Huang J, Yang J. Metabolic dysfunction-associated fatty liver disease can significantly increase the risk of chronic kidney disease in adults with type 2 diabetes. Diabetes Res Clin Pract. 2023;197:110563.","journal-title":"Diabetes Res Clin Pract"},{"issue":"1","key":"2181_CR62","doi-asserted-by":"publisher","first-page":"1996","DOI":"10.1080\/0886022X.2022.2144373","volume":"44","author":"Q Hu","year":"2022","unstructured":"Hu Q, Chen Y, Bao T, Huang Y. Association of metabolic dysfunction-associated fatty liver disease with chronic kidney disease: a Chinese population-based study. Ren Fail. 2022;44(1):1996\u20132005.","journal-title":"Ren Fail"},{"issue":"2","key":"2181_CR63","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1007\/s00592-022-01978-w","volume":"60","author":"Y Zou","year":"2023","unstructured":"Zou Y, Zhao L, Zhang J, Wang Y, Wu Y, Ren H, Wang T, Zhao Y, Xu H, Li L, Tong N, Liu F. Metabolic-associated fatty liver disease increases the risk of end-stage renal disease in patients with biopsy-confirmed diabetic nephropathy: a propensity-matched cohort study. Acta Diabetol. 2023;60(2):225\u201333.","journal-title":"Acta Diabetol"},{"issue":"4","key":"2181_CR64","doi-asserted-by":"publisher","first-page":"101344","DOI":"10.1016\/j.diabet.2022.101344","volume":"48","author":"CY Jung","year":"2022","unstructured":"Jung CY, Koh HB, Park KH, Joo YS, Kim HW, Ahn SH, Park JT, Kim SU. Metabolic dysfunction-associated fatty liver disease and risk of incident chronic kidney disease: A nationwide cohort study. Diabetes Metab. 2022;48(4):101344.","journal-title":"Diabetes Metab"},{"key":"2181_CR65","doi-asserted-by":"publisher","first-page":"1751","DOI":"10.2147\/DMSO.S292926","volume":"14","author":"Y Deng","year":"2021","unstructured":"Deng Y, Zhao Q, Gong R. Association Between Metabolic Associated Fatty Liver Disease and Chronic Kidney Disease: A Cross-Sectional Study from NHANES 2017\u20132018. Diabetes Metab Syndr Obes. 2021;14:1751\u201361.","journal-title":"Diabetes Metab Syndr Obes"},{"key":"2181_CR66","doi-asserted-by":"publisher","first-page":"154433","DOI":"10.1016\/j.metabol.2020.154433","volume":"115","author":"DQ Sun","year":"2021","unstructured":"Sun DQ, Jin Y, Wang TY, Zheng KI, Rios RS, Zhang HY, Targher G, Byrne CD, Yuan WJ, Zheng MH. MAFLD and risk of CKD. Metabolism. 2021;115:154433.","journal-title":"Metabolism"},{"issue":"5","key":"2181_CR67","doi-asserted-by":"publisher","first-page":"102780","DOI":"10.1016\/j.dsx.2023.102780","volume":"17","author":"N Agustanti","year":"2023","unstructured":"Agustanti N, Soetedjo NNM, Damara FA, Iryaningrum MR, Permana H, Bestari MB, Supriyadi R. The association between metabolic dysfunction-associated fatty liver disease and chronic kidney disease: A systematic review and meta-analysis. Diabetes Metab Syndr. 2023;17(5):102780.","journal-title":"Diabetes Metab Syndr"},{"issue":"4","key":"2181_CR68","doi-asserted-by":"publisher","first-page":"407","DOI":"10.17219\/acem\/155017","volume":"32","author":"Y Chen","year":"2023","unstructured":"Chen Y, Bai W, Mao D, Long F, Wang N, Wang K, Shi Q. The relationship between non-alcoholic fatty liver disease and incidence of chronic kidney disease for diabetic and non-diabetic subjects: A meta-analysis. Adv Clin Exp Med. 2023;32(4):407\u201314.","journal-title":"Adv Clin Exp Med"},{"issue":"1","key":"2181_CR69","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1136\/gutjnl-2020-323082","volume":"71","author":"A Mantovani","year":"2022","unstructured":"Mantovani A, Petracca G, Beatrice G, Csermely A, Lonardo A, Schattenberg JM, Tilg H, Byrne CD, Targher G. Non-alcoholic fatty liver disease and risk of incident chronic kidney disease: an updated meta-analysis. Gut. 2022;71(1):156\u201362.","journal-title":"Gut"},{"issue":"2","key":"2181_CR70","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1111\/jdi.13678","volume":"13","author":"Y Hashimoto","year":"2022","unstructured":"Hashimoto Y, Hamaguchi M, Okamura T, Nakanishi N, Obora A, Kojima T, Fukui M. Metabolic associated fatty liver disease is a risk factor for chronic kidney disease. J Diabetes Investig. 2022;13(2):308\u201316.","journal-title":"J Diabetes Investig"},{"issue":"1","key":"2181_CR71","doi-asserted-by":"publisher","first-page":"1796","DOI":"10.1038\/s41598-023-27762-6","volume":"13","author":"SY Kwon","year":"2023","unstructured":"Kwon SY, Park J, Park SH, Lee YB, Kim G, Hur KY, Koh J, Jee JH, Kim JH, Kang M, Jin SM. MAFLD and NAFLD in the prediction of incident chronic kidney disease. Sci Rep. 2023;13(1):1796.","journal-title":"Sci Rep"},{"issue":"3","key":"2181_CR72","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1093\/ndt\/gfac188","volume":"38","author":"M Tanaka","year":"2023","unstructured":"Tanaka M, Mori K, Takahashi S, Higashiura Y, Ohnishi H, Hanawa N, Furuhashi M. Metabolic dysfunction-associated fatty liver disease predicts new onset of chronic kidney disease better than fatty liver or nonalcoholic fatty liver disease. Nephrol Dial Transplant. 2023;38(3):700\u201311.","journal-title":"Nephrol Dial Transplant"},{"issue":"1","key":"2181_CR73","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1210\/clinem\/dgab641","volume":"107","author":"Y Liang","year":"2022","unstructured":"Liang Y, Chen H, Liu Y, Hou X, Wei L, Bao Y, Yang C, Zong G, Wu J, Jia W. Association of MAFLD with diabetes, chronic kidney disease, and cardiovascular disease: A 4.6-year cohort study in China. J Clin Endocrinol Metab. 2022;107(1):88\u201397.","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2181_CR74","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1007\/s12072-023-10486-0","volume":"17","author":"S Chen","year":"2023","unstructured":"Chen S, Pang J, Huang R, Xue H, Chen X. Association of MAFLD with end-stage kidney disease: a prospective study of 337,783 UK Biobank participants. Hepatol Int. 2023;17(3):595\u2013605.","journal-title":"Hepatol Int"},{"issue":"10","key":"2181_CR75","doi-asserted-by":"publisher","first-page":"e3957","DOI":"10.1210\/clinem\/dgab425","volume":"106","author":"G Zuo","year":"2021","unstructured":"Zuo G, Xuan L, Xin Z, Xu Y, Lu J, Chen Y, Dai M, Zhang D, Wang W, Li M, Bi Y, Ning G, Xu M. New Nonalcoholic Fatty Liver Disease and Fibrosis Progression Associate With the Risk of Incident Chronic Kidney Disease. J Clin Endocrinol Metab. 2021;106(10):e3957\u201368.","journal-title":"J Clin Endocrinol Metab"},{"issue":"1 Pt 3","key":"2181_CR76","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1016\/j.jfma.2019.07.007","volume":"119","author":"MH Hsieh","year":"2020","unstructured":"Hsieh MH, Wu KT, Chen YY, Yang JF, Lin WY, Chang NC, Lin CY, Huang CK, Wang CL, Chuang HY, Lin SC, Hsu YK, Tsai YS, Chuang WL, Yu ML, Dai CY. Higher NAFLD fibrosis score is associated with impaired eGFR. J Formos Med Assoc. 2020;119(1 Pt 3):496\u2013503.","journal-title":"J Formos Med Assoc"},{"key":"2181_CR77","doi-asserted-by":"publisher","first-page":"788881","DOI":"10.3389\/fmed.2021.788881","volume":"8","author":"L Marc","year":"2022","unstructured":"Marc L, Mihaescu A, Lupusoru R, Grosu I, Gadalean F, Bob F, Chisavu L, Olariu N, Tucicovschi V, Timar B, Sporea I, Timar R, Schiller A. Liver Steatosis: Better Predictor of CKD in MAFLD Than Liver Fibrosis as Determined by Transient Elastography With Controlled Attenuation Parameter. Front Med (Lausanne). 2022;8:788881.","journal-title":"Front Med (Lausanne)"},{"issue":"8","key":"2181_CR78","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1111\/nep.14186","volume":"28","author":"WK Wong","year":"2023","unstructured":"Wong WK, Chan WK, Ganapathy S, Lim SK. Is metabolic-dysfunction-associated fatty liver disease or advanced liver fibrosis associated with erythropoietin stimulating agent hypo-responsiveness among patients with end-stage kidney disease on haemodialysis? Nephrology (Carlton). 2023;28(8):425\u201333.","journal-title":"Nephrology (Carlton)"},{"issue":"14","key":"2181_CR79","doi-asserted-by":"publisher","first-page":"e030269","DOI":"10.1161\/JAHA.123.030269","volume":"12","author":"D Miyamori","year":"2023","unstructured":"Miyamori D, Tanaka M, Sato T, Endo K, Mori K, Mikami T, Hosaka I, Hanawa N, Ohnishi H, Furuhashi M. Coexistence of Metabolic Dysfunction-Associated Fatty Liver Disease and Chronic Kidney Disease Is a More Potent Risk Factor for Ischemic Heart Disease. J Am Heart Assoc. 2023;12(14):e030269.","journal-title":"J Am Heart Assoc"},{"issue":"1","key":"2181_CR80","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1186\/s12916-023-02891-x","volume":"21","author":"TJ Hydes","year":"2023","unstructured":"Hydes TJ, Kennedy OJ, Buchanan R, Cuthbertson DJ, Parkes J, Fraser SDS, Roderick P. The impact of non-alcoholic fatty liver disease and liver fibrosis on adverse clinical outcomes and mortality in patients with chronic kidney disease: a prospective cohort study using the UK Biobank. BMC Med. 2023;21(1):185.","journal-title":"BMC Med"},{"issue":"3","key":"2181_CR81","doi-asserted-by":"publisher","first-page":"386","DOI":"10.21037\/hbsn-22-421","volume":"12","author":"DQ Sun","year":"2023","unstructured":"Sun DQ, Targher G, Byrne CD, Wheeler DC, Wong VW, Fan JG, Tilg H, Yuan WJ, Wanner C, Gao X, Long MT, Kanbay M, Nguyen MH, Navaneethan SD, Yilmaz Y, Huang Y, Gani RA, Marzuillo P, Boursier J, Zhang H, Jung CY, Chai J, Valenti L, Papatheodoridis G, Musso G, Wong YJ, El-Kassas M, M\u00e9ndez-S\u00e1nchez N, Sookoian S, Pavlides M, Duseja A, Holleboom AG, Shi J, Chan WK, Fouad Y, Yang J, Treeprasertsuk S, Cortez-Pinto H, Hamaguchi M, Romero-Gomez M, Al Mahtab M, Ocama P, Nakajima A, Dai C, Eslam M, Wei L, George J, Zheng MH. An international Delphi consensus statement on metabolic dysfunction-associated fatty liver disease and risk of chronic kidney disease. Hepatobiliary Surg Nutr. 2023;12(3):386\u2013403.","journal-title":"Hepatobiliary Surg Nutr"},{"key":"2181_CR82","doi-asserted-by":"publisher","unstructured":"Mori K, Tanaka M, Sato T, Akiyama Y, Endo K, Ogawa T, Suzuki T, Aida H, Kawaharata W, Nakata K, Hosaka I, Umetsu A, Hanawa N, Furuhashi M. Metabolic dysfunction-associated steatotic liver disease (SLD) and alcohol-associated liver disease, but not SLD without metabolic dysfunction, are independently associated with new onset of chronic kidney disease during a 10-year follow-up period. Hepatol Res. 2024. https:\/\/doi.org\/10.1111\/hepr.14097","DOI":"10.1111\/hepr.14097"},{"issue":"4","key":"2181_CR83","doi-asserted-by":"publisher","first-page":"e0299507","DOI":"10.1371\/journal.pone.0299507","volume":"19","author":"M Gurun","year":"2024","unstructured":"Gurun M, Brennan P, Handjiev S, Khatib A, Leith D, Dillon JF, Byrne CJ. Increased risk of chronic kidney disease and mortality in a cohort of people diagnosed with metabolic dysfunction associated steatotic liver disease with hepatic fibrosis. PLoS ONE. 2024;19(4):e0299507.","journal-title":"PLoS ONE"},{"issue":"1","key":"2181_CR84","doi-asserted-by":"publisher","first-page":"101506","DOI":"10.1016\/j.diabet.2023.101506","volume":"50","author":"J Bilson","year":"2024","unstructured":"Bilson J, Mantovani A, Byrne CD, Targher G. Steatotic liver disease, MASLD and risk of chronic kidney disease. Diabetes Metab. 2024;50(1):101506.","journal-title":"Diabetes Metab"},{"issue":"3","key":"2181_CR85","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1016\/j.cgh.2021.11.038","volume":"21","author":"GEH Lim","year":"2023","unstructured":"Lim GEH, Tang A, Ng CH, Chin YH, Lim WH, Tan DJH, Yong JN, Xiao J, Lee CW, Chan M, Chew NW, Xuan Tan EX, Siddiqui MS, Huang D, Noureddin M, Sanyal AJ, Muthiah MD. An Observational Data Meta-analysis on the Differences in Prevalence and Risk Factors Between MAFLD vs NAFLD. Clin Gastroenterol Hepatol. 2023;21(3):619-629.e7.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"12","key":"2181_CR86","doi-asserted-by":"publisher","first-page":"3018","DOI":"10.1111\/liv.14675","volume":"40","author":"S Yamamura","year":"2020","unstructured":"Yamamura S, Eslam M, Kawaguchi T, Tsutsumi T, Nakano D, Yoshinaga S, Takahashi H, Anzai K, George J, Torimura T. MAFLD identifies patients with significant hepatic fibrosis better than NAFLD. Liver Int. 2020;40(12):3018\u201330.","journal-title":"Liver Int"},{"issue":"6","key":"2181_CR87","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1016\/j.jhep.2021.07.035","volume":"75","author":"D Kim","year":"2021","unstructured":"Kim D, Konyn P, Sandhu KK, Dennis BB, Cheung AC, Ahmed A. Metabolic dysfunction-associated fatty liver disease is associated with increased all-cause mortality in the United States. J Hepatol. 2021;75(6):1284\u201391.","journal-title":"J Hepatol"},{"key":"2181_CR88","doi-asserted-by":"publisher","first-page":"693507","DOI":"10.3389\/fmed.2021.693507","volume":"8","author":"Q Huang","year":"2021","unstructured":"Huang Q, Zou X, Wen X, Zhou X, Ji L. NAFLD or MAFLD: Which Has Closer Association With All-Cause and Cause-Specific Mortality? Results From NHANES III. Front Med (Lausanne). 2021;8:693507.","journal-title":"Front Med (Lausanne)"},{"issue":"6","key":"2181_CR89","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1007\/s12072-021-10252-0","volume":"15","author":"HH Liu","year":"2021","unstructured":"Liu HH, Cao YX, Jin JL, Guo YL, Zhu CG, Wu NQ, Gao Y, Xu RX, Dong Q, Zheng MH, Li JJ. Metabolic-associated fatty liver disease and major adverse cardiac events in patients with chronic coronary syndrome: a matched case-control study. Hepatol Int. 2021;15(6):1337\u201346.","journal-title":"Hepatol Int"},{"issue":"3","key":"2181_CR90","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1161\/ATVBAHA.122.318661","volume":"43","author":"KC Sung","year":"2023","unstructured":"Sung KC, Yoo TK, Lee MY, Byrne CD, Zheng MH, Targher G. Comparative Associations of Nonalcoholic Fatty Liver Disease and Metabolic Dysfunction-Associated Fatty Liver Disease With Coronary Artery Calcification: A Cross-Sectional and Longitudinal Cohort Study. Arterioscler Thromb Vasc Biol. 2023;43(3):482\u201391.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"6","key":"2181_CR91","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1007\/s12072-022-10407-7","volume":"16","author":"H Lee","year":"2022","unstructured":"Lee H, Lim TS, Kim SU, Kim HC. Long-term cardiovascular outcomes differ across metabolic dysfunction-associated fatty liver disease subtypes among middle-aged population. Hepatol Int. 2022;16(6):1308\u201317.","journal-title":"Hepatol Int"}],"container-title":["Current Cardiology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11886-024-02181-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11886-024-02181-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11886-024-02181-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T09:05:56Z","timestamp":1772096756000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11886-024-02181-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,13]]},"references-count":91,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["2181"],"URL":"https:\/\/doi.org\/10.1007\/s11886-024-02181-9","relation":{},"ISSN":["1523-3782","1534-3170"],"issn-type":[{"value":"1523-3782","type":"print"},{"value":"1534-3170","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,13]]},"assertion":[{"value":"15 October 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 January 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}],"article-number":"19"}}